Jagsonpal Pharmaceuticals Ltd

📊 Jagsonpal Pharma FY2026 Results: Revenue Up 6.9% to ₹2,872M, But Net Profit Declines 📉

• Revenue from operations for FY 2026 was ₹2,872.25 million, up from ₹2,687.16 million in FY 2025

• Net profit for FY 2026 was ₹430.82 million, compared to ₹553.61 million in FY 2025

• Earnings per share (basic) for FY 2026 were ₹6.40, down from ₹8.26 in FY 2025

• Exceptional item of ₹20.79 million recorded due to impact of new labour codes on employee benefits

• Board recommended a dividend of ₹4 per equity share (200%) for FY ended March 31, 2026

• Board approved buy-back of up to 1.6 million equity shares at ₹250 per share, totaling ₹400 million

• Company granted 1,152,500 stock options and allotted 180,980 equity shares under Employee Stock Option Plan 2022